m4 leukemia is also known as acute granulomonocytic leukemia. m5 leukemia is known as acute mononuclear cell leukemia, and are two subtypes of acute non-lymphoblastic leukemia. The cure rate cannot be accurately determined and is related to the degree of disease risk and age. Those with a lower risk stratification have a relatively higher cure rate, and those with a higher risk stratification have a relatively lower cure rate. For example, some studies have shown that different age groups receive the same treatment, <50 years old, 60-69 years old, >70 years old patients with a cure rate of 70%, 52% and 26%, respectively. With the growth of age, the physiological function of the tissues and structures of the organs of the elderly appear degenerative changes, affecting the body’s absorption, distribution, metabolism and excretion of drugs, directly affecting the efficacy of drugs and the occurrence of adverse reactions. The degree of malignancy of m4m5 leukemia is higher, the treatment is more difficult, and the relapse rate is also higher if it is not treated by transplantation. With the progress of medical level, the efficacy of combined chemotherapy and bone marrow transplantation has made great progress, and it is recommended to standardize the treatment under the guidance of the doctor and regular review. Specific drugs include cytarabine and Zoerythromycin.